Category Archives: Transgender medicine

Use of puberty blockers in transgender girls, effects on genital tissue development, and vaginoplasty options

Background and description of the issue GnRH analogue medications such as Lupron, Decapeptyl, and Supprelin LA have been in use since the early 1990s to halt natal pubertal development at Tanner stage 2 or 3 in transgender adolescents with persistent … Continue reading

Posted in Endocrinology, Outcomes of transition, Surgery, Trans youth, Transgender medicine | Tagged , , , , , | Leave a comment

Large study of trans people in the Netherlands shows growing numbers seeking treatment, low regret rates

Medical transition by trans people, its prevalence and demographics, and rates of regret of treatment are perennial subjects of public curiosity and media controversy. With unfortunate frequency, this has taken the form of scaremongering that depicts the growing numbers of … Continue reading

Posted in Outcomes of transition, Regret and detransition, Statistics and demographics, Transgender medicine | Tagged , , | Leave a comment

Update on case reports: Cyproterone acetate and meningioma in trans women

Previously: Cyproterone acetate and meningioma risk in trans women (March 2018) Disclaimer: I am not a doctor, and this is not medical advice. Do not take any medication without appropriate medical supervision. Summary Cyproterone acetate (CPA) is commonly used as … Continue reading

Posted in Endocrinology, Oncology, Progestogens, Transgender medicine | Tagged , , | 1 Comment

4thWaveNow “ROGD parent” Brie Jontry doesn’t know what histrelin is

4thWaveNow, one of the three survey respondent recruitment sites for the badly flawed study of an alleged new “rapid onset gender dysphoria” condition, has long served as a clearinghouse for questionable notions about puberty-blocking medications used for transgender youth. These … Continue reading

Posted in Endocrinology, Health care, Trans youth, Transgender medicine | Tagged , , , , , , , | Leave a comment

Additional information on transition treatment for trans women with BRCA1 or BRCA2 mutations

I’ve previously covered existing research on hormone therapy for trans women who are at an increased risk of breast cancer due to BRCA1 or BRCA2 mutations. As transitioning with estrogen induces the growth of breast tissue just as in cis … Continue reading

Posted in Breast, Endocrinology, Health care, Oncology, Surgery, Transgender medicine | Tagged , | Leave a comment